Literature DB >> 8676077

Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10.

F Gerosa1, C Paganin, D Peritt, F Paiola, M T Scupoli, M Aste-Amezaga, I Frank, G Trinchieri.   

Abstract

Interleukin-12 (IL-12) induces differentiation of T helper 1 (Th1) cells, primarily through its ability to prime T cells for high interferon-gamma (IFN-gamma) production. We now report that the presence of IL-12 during the first several days of in vitro clonal expansion in limiting dilution cultures of polyclonally stimulated human peripheral blood CD4+ and CD8+ T cells also induces stable priming for high IL-10 production. This effect was demonstrated with T cells from both healthy donors and HIV+ patients. Priming for IL-4 production, which requires IL-4, was maximum in cultures containing both IL-12 and IL-4. IL-4 modestly inhibited the IL-12-induced priming for IFN-gamma, but almost completely suppressed the priming for IL-10 production. A proportion of the clones generated from memory CD45RO+ cells, but not those generated from naive CD45RO- CD4+ T cells, produced some combinations of IFN-gamma, IL-10, and IL-4 even in the absence of IL-12 and IL-4, suggesting in vivo cytokine priming; virtually all CD4+ clones generated from either CD45RO(-) or (+) cells, however, produced high levels of both IFN-gamma and IL-10 when IL-12 was present during expansion. These results indicate that each Th1-type (IFN-gamma) and Th2-type (IL-4 and IL-10) cytokine gene is independently regulated in human T cells and that the dichotomy between T cells with the cytokine production pattern of Th1 and Th2 cells is not due to a direct differentiation-inducing effect of immunoregulatory cytokines, but rather to secondary selective mechanisms. Particular combinations of cytokines induce a predominant generation of T cell clones with anomalous patterns of cytokine production (e.g., IFN-gamma and IL-4 or IFN-gamma and IL-10) that can also be found in a proportion of fresh peripheral blood T cells with "memory" phenotype or clones generated from them and that may identify novel Th subsets with immunoregulatory functions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8676077      PMCID: PMC2192598          DOI: 10.1084/jem.183.6.2559

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  57 in total

1.  Developmental commitment to the Th2 lineage by extinction of IL-12 signaling.

Authors:  S J Szabo; N G Jacobson; A S Dighe; U Gubler; K M Murphy
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

2.  The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

Authors:  L C Afonso; T M Scharton; L Q Vieira; M Wysocka; G Trinchieri; P Scott
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

3.  In vitro maturation of human neonatal CD4 T lymphocytes. I. Induction of IL-4-producing cells after long-term culture in the presence of IL-4 plus either IL-2 or IL-12.

Authors:  C Y Wu; C E Demeure; M Gately; F Podlaski; H Yssel; M Kiniwa; G Delespesse
Journal:  J Immunol       Date:  1994-02-01       Impact factor: 5.422

4.  High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane.

Authors:  S B Cohen; P D Katsikis; C Q Chu; H Thomssen; L M Webb; R N Maini; M Londei; M Feldmann
Journal:  Arthritis Rheum       Date:  1995-07

5.  IL-12 inhibits the production of IL-4 and IL-10 in allergen-specific human CD4+ T lymphocytes.

Authors:  J D Marshall; H Secrist; R H DeKruyff; S F Wolf; D T Umetsu
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

6.  Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro.

Authors:  M Clerici; D R Lucey; J A Berzofsky; L A Pinto; T A Wynn; S P Blatt; M J Dolan; C W Hendrix; S F Wolf; G M Shearer
Journal:  Science       Date:  1993-12-10       Impact factor: 47.728

7.  Differential regulation of interleukin-12 (IL-12), tumor necrosis factor alpha, and IL-1 beta production in human myeloid leukemia cell lines and peripheral blood mononuclear cells.

Authors:  M Kubin; J M Chow; G Trinchieri
Journal:  Blood       Date:  1994-04-01       Impact factor: 22.113

8.  Effects of IL-12 on helper T cell-dependent immune responses in vivo.

Authors:  A J McKnight; G J Zimmer; I Fogelman; S F Wolf; A K Abbas
Journal:  J Immunol       Date:  1994-03-01       Impact factor: 5.422

9.  Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones.

Authors:  R Manetti; F Gerosa; M G Giudizi; R Biagiotti; P Parronchi; M P Piccinni; S Sampognaro; E Maggi; S Romagnani; G Trinchieri
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

10.  Impaired interleukin 12 production in human immunodeficiency virus-infected patients.

Authors:  J Chehimi; S E Starr; I Frank; A D'Andrea; X Ma; R R MacGregor; J Sennelier; G Trinchieri
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  79 in total

1.  Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Th1 to the Th2 pathway.

Authors:  T S Kim; B Y Kang; M H Lee; Y K Choe; S Y Hwang
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

2.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

Authors:  Sid P Kerkar; Pawel Muranski; Andrew Kaiser; Andrea Boni; Luis Sanchez-Perez; Zhiya Yu; Douglas C Palmer; Robert N Reger; Zachary A Borman; Ling Zhang; Richard A Morgan; Luca Gattinoni; Steven A Rosenberg; Giorgio Trinchieri; Nicholas P Restifo
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

Review 4.  Immunotherapeutic approaches for the treatment of breast cancer.

Authors:  K L Knutson; K Schiffman; K Rinn; M L Disis
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 5.  Plasmacytoid dendritic cells: in search of their niche in immune responses.

Authors:  Winfried Barchet; Amanda Blasius; Marina Cella; Marco Colonna
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

6.  Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa.

Authors:  H A Haeberle; M Kubin; K B Bamford; R Garofalo; D Y Graham; F El-Zaatari; R Karttunen; S E Crowe; V E Reyes; P B Ernst
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 7.  Glycogen synthase kinase 3: a point of convergence for the host inflammatory response.

Authors:  Huizhi Wang; Jonathan Brown; Michael Martin
Journal:  Cytokine       Date:  2010-11-23       Impact factor: 3.861

8.  Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression.

Authors:  S L Giannini; W Al-Saleh; H Piron; N Jacobs; J Doyen; J Boniver; P Delvenne
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

9.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.

Authors:  C Andrew Stewart; Hannah Metheny; Noriho Iida; Loretta Smith; Miranda Hanson; Folkert Steinhagen; Robert M Leighty; Axel Roers; Christopher L Karp; Werner Müller; Giorgio Trinchieri
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

Review 10.  Cell type-specific regulation of IL-10 expression in inflammation and disease.

Authors:  Christian M Hedrich; Jay H Bream
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.